- Processing Solutions
- Agitators
- Asset Management
- Automation
- Blowers & Fans
- Centrifuges
- Chillers
- Compressors
- Conveyors
- Dryers & Evaporators
- Feeders
- Filtration & Separation
- Flowmeters
- Fluid Flow
- Heat Exchangers
- Instrumentation
- Level Measurement
- Maintenance & Safety
- Mixing & Blending
- Motors & Drives
- Oil Skimmers
- Piping & Tubing
- Packaging Equipment
- Powder & Bulk Solids
- Process Control
- Pumps & Seals
- Size Reduction
- Tanks & Vessels
- Valves & Actuators
- Weighing
- More
- Newsletters
- White Papers
- Buyer's Guide
- Videos
- Events
- Advertise
More
The Associated Press reports, federal regulators need an additional three months to complete a review of an experimental blood thinner made by AstraZeneca, the company said. In July, FDA advisory committee members voted 7 to 1 to recommend the approval of Brilinta in pat ients with acute coronary syndrome, or blocked arteries. The committee''s advice is not binding, but the FDA usually follows it. The U.S. Food and Drug Administration review that was scheduled to be completed Thursday was pushed back to Dec. 16, the company said. An international study conducted by AstraZeneca showed that pat ients taking Brilinta versus Plavix were less likely to experience various heart-related problems. But U.S. pat ients studied were more likely to report heart problems while taking Brilinta. The blood thinner market is currently dominated by Plavix, a Sanofi-Aventis SA and Bristol-Myers Squibb Co. product that brought in $9.1 billion in global sales last year.
